Looks like most everyone has left this board. Hate to see it because I really appreciated hearing from some of the posters.

I think the sale of DX division could help turn this thing around. Also, MANF for RP, from what I have been able to read, would be a nice asset for a big pharma. Either would infuse some cash and help us move forward with additional MANF indications and/or ESS. Hoping GC has another surprise up his sleeve and he drops it on us soon.